Industry
Biotechnology
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 28, 2023 | 1:23 pm
Portfolio Pulse from Lara Goldstein
August 24, 2023 | 7:49 pm
Portfolio Pulse from Benzinga Newsdesk
August 24, 2023 | 5:57 am
Portfolio Pulse from richadhand@benzinga.com
August 22, 2023 | 1:41 pm
Portfolio Pulse from Happy Mohamed
August 17, 2023 | 12:04 pm
Portfolio Pulse from Benzinga Insights
August 15, 2023 | 9:00 pm
Portfolio Pulse from richadhand@benzinga.com
August 15, 2023 | 3:50 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.